Panel Discussion: How Is Translational Proteomics Shaping the Future of Drug Target Discovery?

28 Jan 2026
Proteogenomics & Translational Omics Stage
  • How is proteomics helping researchers move beyond genomics to identify more actionable drug targets, particularly in complex or poorly understood diseases? 

  • What are some recent breakthroughs or case studies where proteomics has directly influenced the discovery or validation of a novel drug target? 

  • How are advances in mass spectrometry, single-cell proteomics, or spatial proteomics enhancing our ability to identify meaningful targets? 

  • What are the biggest challenges in integrating proteomics with other omics data (e.g. transcriptomics, metabolomics) and how are organizations overcoming them in drug discovery pipelines? 

Speakers
Praveen Surendran
Praveen Surendran, Associate Director of Applied and Statistical Genetics - GSK 
Oliver Burren
Oliver Burren, Director Genome Analysis -  AstraZeneca 
Marcus Bantscheff
Marcus Bantscheff, Head of Proteomics and Metabolomics Platofrm - Roche